Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Deferred Tax (2022 - 2023)

Syndax Pharmaceuticals has reported Long-Term Deferred Tax over the past 2 years, most recently at $53.7 million for Q4 2023.

  • Quarterly results put Long-Term Deferred Tax at $53.7 million for Q4 2023, up 9.82% from a year ago — trailing twelve months through Dec 2023 was $53.7 million (up 9.82% YoY), and the annual figure for FY2023 was $53.7 million, up 9.82%.
  • Long-Term Deferred Tax for Q4 2023 was $53.7 million at Syndax Pharmaceuticals, up from $48.9 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for SNDX hit a ceiling of $53.7 million in Q4 2023 and a floor of $48.9 million in Q4 2022.